BriaCell reports 100% resolution of brain metastasis in breast cancer patient with “eye-bulging” tumor

• The dramatic anti-tumor response includes complete resolution of brain metastasis in the right temporal lobe in a patient with eye-bulging metastatic breast cancer

• One heavily pretreated patient had failed 8 prior therapies, including antibody medications conjugate (ADC) therapy and continues to receive BriaCell treatment

PHILADELPHIA and VANCOUVER, British Columbia, Oct. 1, 2024 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer treatment, is pleased to report a dramatic anti-tumor response including to report the complete resolution of temporal lobe breast cancer metastases in a patient treated with BriaCell’s Bria-IMT™ plus an immune checkpoint inhibitor regimen in the Phase 2 trial. The patient showed an initial partial response to the brain lesion after 2 months with no apparent disease after 8 and 11 months of treatment.

The heavily pretreated patient, who had failed 8 prior therapies, including ADC therapy, previously demonstrated significant reduction in her eye-bulging orbital tumor and is continuing treatment with Bria-IMT™ therapy. She has completed 17 cycles of treatment and has been participating in BriaCell’s Phase 2 trial for 12 months. Also notable is a sustained decline in their tumor markers, which confirms the imaging results of significant tumor reduction.

Figure 1: The Bria-IMT™ regimen resulted in 100% tumor resolution in the right temporal lobe area of ​​the brain

As shown in Figure 1, the right temporal lobe lesion is no longer evident in images taken after 8 months and 11 months of Bria-IMT™ combination therapy. The orbital lesion continued to shrink significantly (Figure 2). In addition, their tumor markers (blood tests that correlate with the amount of tumor in the body) continue to decrease significantly compared to pre-treatment levels.

Figure 2: The Bria-IMT™ regimen resulted in near complete resolution of the breast cancer tumor in the right orbit (behind the eye).

“The potential therapeutic effect of Bria-IMT™ is unprecedented in metastatic breast cancer (MBC) with brain metastases. “Our clinical results showing significant tumor shrinkage in metastatic brain lesions may transform the way we treat MBC patients with brain metastases and provide hope to cancer patients and their families battling this devastating disease,” explained Dr. William V. Williams, BriaCell President and CEO. “These results support Bria-IMT™ as a potential new therapeutic option for MBC patients with brain metastases. We look forward to studying the subset of patients with brain metastases in our ongoing pivotal Phase 3 study in metastatic breast cancer.”

“We believe that the complete tumor resolution in this patient with brain metastases, as well as other cases of significant clinical anticancer responses in our Phase 2 MBC patients with brain metastases, highlight the potential use of Bria-IMT™ in the treatment of similar MBC patients.”, commented Dr. Giuseppe Del Priore, Chief Medical Officer of BriaCell. “The long duration of therapy, now one year, demonstrates the excellent tolerability of the Bria-IMT™ regimen in combination with an immune checkpoint inhibitor used in our pivotal phase 3 study.”

About BriaCell Therapeutics Corp.

BriaCell is a clinical-stage biotechnology company developing novel immunotherapies to transform cancer treatment. For more information, visit https://briacell.com/.

Safe haven

This press release contains “forward-looking statements” that are subject to significant risks and uncertainties. All statements contained in this press release, other than statements of historical fact, are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “ could”, “plan”, “potential”, “predict”, “project”, “aim”, “aim”, “should”, “will”, “would” or the negative thereof words or other similar expressions, also if not all forward-looking statements contain these words. Forward-looking statements, including those regarding BriaCell repeating positive data in its ongoing pivotal Phase 3 study; BriaCell’s Bria-IMT™ regimen brings relief to cancer patients whose medical needs remain unmet. and the development of the Bria-IMT™ regimen as a treatment option for patients with metastatic breast cancer are based on BriaCell’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. In addition, certain forward-looking statements are based on assumptions about future events that may not prove to be accurate. These and other risks and uncertainties are described in more detail under the heading “Risks and Uncertainties” in the Company’s most recent Management’s Discussion and Analysis, under the heading “Risk Factors” in the Company’s most recent annual information form and under “Risks and Uncertainties” in the others The Company’s filings with Canadian securities regulators and the United States Securities and Exchange Commission, all of which are available under the Company’s profiles on SEDAR+ at www.sedarplus.ca and on EDGAR www.sec.gov. The forward-looking statements contained in this release are made as of this date and BriaCell Therapeutics Corp. assumes no obligation to update this information except as required by applicable law.

Neither the Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact information

Company contact:
William V. Williams, MD
President and CEO
1-888-485-6340
[email protected]

Media relations:
Jules Abraham
CORE IR
[email protected]

Investor Relations Contact:
CORE IR
[email protected]

Photos accompanying this announcement are available at

https://www.globenewswire.com/NewsRoom/AttachmentNg/0a328ad2-c48d-43bf-ae04-0b69da4d3f3f

https://www.globenewswire.com/NewsRoom/AttachmentNg/eea9560e-c63a-4001-a5b7-6a07caf3c91b